GlassScriptPhysician profile
Candice Hester
NPI 1043784820
$8,417.17
in general payments reported to CMS, 2019-2025
31 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,447 · 2022: $2,674 · 2023: $1,054 · 2024: $1,105 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375 · Travel and Lodging: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.60 |
| Travel and Lodging | $921.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,657.80 | 2021-2025 | Lifevest |
| Philips North America LLC | $1,643.02 | 2022 | |
| Abbott Laboratories | $1,299.69 | 2024-2025 | Cardiomems, Xact, Esprit |
| E.R. Squibb & Sons, L.L.C. | $586.86 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $531.77 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $490.88 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $312.35 | 2021 | |
| Merck Sharp & Dohme LLC | $267.89 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $245.88 | 2021-2022 | |
| Amgen INC. | $219.78 | 2021-2025 | Repatha, Repatha |
| Endologix LLC | $173.06 | 2025 | Endocross Device, Torus Stent Graft System |
| Boston Scientific Corporation | $123.78 | 2025 | Enroute Transcarotid Neuroprotection System |
| Cvrx, INC. | $117.58 | 2024-2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $93.21 | 2022-2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $88.15 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.84 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $68.17 | 2021-2025 | Opsynvi |
| Kowa Pharmaceuticals America, INC. | $62.60 | 2021 | |
| Baxter Healthcare | $58.18 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $43.65 | 2024 | Venaseal, Intellis Adaptivestim |
| Pfizer INC. | $39.79 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $36.04 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $29.05 | 2022-2023 | Optimizer |
| Kerecis Limited | $25.20 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Nevro Corp. | $24.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.15 | 2022 | |
| Bolton Medical INC | $17.12 | 2024 | Treo Abdominal Stent-Graft System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.54 | 2022 | |
| Angiodynamics, INC. | $13.42 | 2022 | |
| Bard Peripheral Vascular, INC. | $13.40 | 2023 | Rotarexs 6 F X 135 Cm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.